Silo Pharma, Inc. SILO
We take great care to ensure that the data presented and summarized in this overview for Silo Pharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SILO
View all-
Jim Simons Renaissance Technologies LLC | New York, Ny227KShares$204,3050.0% of portfolio
-
Geode Capital Management, LLC Boston, MA30.8KShares$27,6840.0% of portfolio
-
Virtu Financial LLC New York, NY25.6KShares$23,0530.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA16.3KShares$14,7000.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il14.4KShares$12,9350.0% of portfolio
-
State Street Corp Boston, MA12.5KShares$11,2500.0% of portfolio
-
Federation Des Caisses Desjardins Du Quebec Levis, A86KShares$5,4000.0% of portfolio
-
Tower Research Capital LLC (Trc) New York, NY4.06KShares$3,6540.0% of portfolio
-
Lazard Asset Management LLC New York, NY1.02KShares$9160.0% of portfolio
-
Westside Investment Management, Inc.94Shares$840.0% of portfolio
Latest Institutional Activity in SILO
Top Purchases
Top Sells
About SILO
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company focuses on merging traditional therapeutics with psychedelic research for patients with depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. It has a scientific research agreement with the University of Maryland, The Regents of the University of California, and Columbia University. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.
Insider Transactions at SILO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 13
2024
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
2,500
+1.31%
|
$0
$0.84 P/Share
|
|
Nov 22
2024
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
2,500
+1.33%
|
$0
$0.9 P/Share
|
|
Nov 20
2024
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
2,500
+1.35%
|
$0
$0.95 P/Share
|
|
Jun 12
2024
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
4,438
+2.4%
|
$4,438
$1.11 P/Share
|
|
Jun 11
2024
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
562
+0.32%
|
$562
$1.08 P/Share
|
|
Apr 05
2024
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
400
+0.23%
|
$800
$2.03 P/Share
|
|
Apr 04
2024
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
600
+0.34%
|
$600
$1.96 P/Share
|
|
Apr 01
2024
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
1,100
+0.63%
|
$1,100
$1.91 P/Share
|
|
Mar 28
2024
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
3,408
+1.93%
|
$3,408
$1.94 P/Share
|
|
Dec 20
2023
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
200
+0.12%
|
$200
$1.61 P/Share
|
|
Dec 19
2023
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
500
+0.29%
|
$500
$1.63 P/Share
|
|
Dec 15
2023
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
900
+0.53%
|
$900
$1.52 P/Share
|
|
Dec 14
2023
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
200
+0.12%
|
$200
$1.5 P/Share
|
|
Dec 07
2023
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
324
+0.19%
|
$324
$1.36 P/Share
|
|
Dec 06
2023
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
76
+0.05%
|
$76
$1.34 P/Share
|
|
Dec 05
2023
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
600
+0.36%
|
$600
$1.39 P/Share
|
|
Nov 30
2023
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
1,000
+0.59%
|
$1,000
$1.53 P/Share
|
|
Nov 29
2023
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
1,000
+0.6%
|
$1,000
$1.57 P/Share
|
|
Nov 27
2023
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
250
+0.15%
|
$250
$1.78 P/Share
|
|
Nov 22
2023
|
Eric Weisblum CEO and President |
BUY
Open market or private purchase
|
Direct |
400
+0.24%
|
$400
$1.68 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 18.7K shares |
|---|